GlobeImmune is focused the development of therapeutic Tarmogen vaccines for the treatment of infectious diseases and cancer. Tarmogen vaccines are whole, heat-killed recombinant Saccharomyces cerevisiae yeast cells engineered to produce one or more target disease antigens, such as viral proteins or cancer-associated proteins. The company’s lead infectious disease product candidate, GI-5005, is a Tarmogen vaccine in Phase II development for the treatment of chronic hepatitis C infection (HCV).
The collaboration with Gilead aims to generate therapeutic vaccine products that have a specific HBV DNA antigens cloned into S. cerevisiae. The firms anticipate that combining a therapeutic vaccine with oral suppressive antiviral therapy will help increase surface antigen (HBsAg) loss with seroconversion. “Based on the proof-of-concept studies in hepatitis C infection, we believe that the combination of GlobeImmune’s Tarmogen immunotherapy products with oral suppressive antiviral therapy will help eliminate the cells harboring the hepatitis B virus, thus increasing seroconversion within a finite period,” remarks David Apelian, M.D., senior vp of R&D, and CMO at GlobeImmune.
Read more.....
0 comments:
Post a Comment